vs
BioLineRx Ltd.（BLRX）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
UNITED THERAPEUTICS Corp的季度营收约是BioLineRx Ltd.的2599.3倍（$790.2M vs $304.0K）。UNITED THERAPEUTICS Corp净利率更高（46.1% vs -1296.1%，领先1342.2%）。UNITED THERAPEUTICS Corp同比增速更快（7.4% vs -94.4%）。UNITED THERAPEUTICS Corp自由现金流更多（$173.3M vs $-2.8M）
BioLineRx（简称BioLine）是一家专注于药物开发的上市企业，总部设立于以色列，公司股份同时在美国纳斯达克资本市场和以色列特拉维夫证券交易所挂牌交易。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
BLRX vs UTHR — 直观对比
营收规模更大
UTHR
是对方的2599.3倍
$304.0K
营收增速更快
UTHR
高出101.7%
-94.4%
净利率更高
UTHR
高出1342.2%
-1296.1%
自由现金流更多
UTHR
多$176.1M
$-2.8M
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $304.0K | $790.2M |
| 净利润 | $-3.9M | $364.3M |
| 毛利率 | 76.3% | 86.9% |
| 营业利润率 | -757.6% | 45.1% |
| 净利率 | -1296.1% | 46.1% |
| 营收同比 | -94.4% | 7.4% |
| 净利润同比 | -914.0% | 20.9% |
| 每股收益（稀释后） | $0.00 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLRXUTHR
| Q4 25 | — | $790.2M | ||
| Q3 25 | — | $799.5M | ||
| Q2 25 | $304.0K | $798.6M | ||
| Q1 25 | — | $794.4M | ||
| Q4 24 | — | $735.9M | ||
| Q3 24 | — | $748.9M | ||
| Q2 24 | $5.4M | $714.9M | ||
| Q1 24 | — | $677.7M |
净利润BLRXUTHR
| Q4 25 | — | $364.3M | ||
| Q3 25 | — | $338.7M | ||
| Q2 25 | $-3.9M | $309.5M | ||
| Q1 25 | — | $322.2M | ||
| Q4 24 | — | $301.3M | ||
| Q3 24 | — | $309.1M | ||
| Q2 24 | $484.0K | $278.1M | ||
| Q1 24 | — | $306.6M |
毛利率BLRXUTHR
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | 76.3% | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | 83.4% | 89.1% | ||
| Q1 24 | — | 89.2% |
营业利润率BLRXUTHR
| Q4 25 | — | 45.1% | ||
| Q3 25 | — | 48.6% | ||
| Q2 25 | -757.6% | 45.6% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 48.6% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | -107.0% | 44.7% | ||
| Q1 24 | — | 52.6% |
净利率BLRXUTHR
| Q4 25 | — | 46.1% | ||
| Q3 25 | — | 42.4% | ||
| Q2 25 | -1296.1% | 38.8% | ||
| Q1 25 | — | 40.6% | ||
| Q4 24 | — | 40.9% | ||
| Q3 24 | — | 41.3% | ||
| Q2 24 | 9.0% | 38.9% | ||
| Q1 24 | — | 45.2% |
每股收益（稀释后）BLRXUTHR
| Q4 25 | — | $7.66 | ||
| Q3 25 | — | $7.16 | ||
| Q2 25 | $0.00 | $6.41 | ||
| Q1 25 | — | $6.63 | ||
| Q4 24 | — | $6.23 | ||
| Q3 24 | — | $6.39 | ||
| Q2 24 | $0.00 | $5.85 | ||
| Q1 24 | — | $6.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.2M | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $20.1M | $7.1B |
| 总资产 | $43.3M | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLRXUTHR
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | $7.2M | $3.0B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | $9.6M | $3.0B | ||
| Q1 24 | — | $2.7B |
股东权益BLRXUTHR
| Q4 25 | — | $7.1B | ||
| Q3 25 | — | $6.6B | ||
| Q2 25 | $20.1M | $7.2B | ||
| Q1 25 | — | $6.8B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | $13.9M | $5.7B | ||
| Q1 24 | — | $5.3B |
总资产BLRXUTHR
| Q4 25 | — | $7.9B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | $43.3M | $7.9B | ||
| Q1 25 | — | $7.7B | ||
| Q4 24 | — | $7.4B | ||
| Q3 24 | — | $7.1B | ||
| Q2 24 | $64.6M | $6.7B | ||
| Q1 24 | — | $6.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.8M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | $-2.8M | $173.3M |
| 自由现金流率自由现金流/营收 | -914.1% | 21.9% |
| 资本支出强度资本支出/营收 | 3.6% | 21.9% |
| 现金转化率经营现金流/净利润 | — | 0.95× |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流BLRXUTHR
| Q4 25 | — | $346.2M | ||
| Q3 25 | — | $562.1M | ||
| Q2 25 | $-2.8M | $191.7M | ||
| Q1 25 | — | $461.2M | ||
| Q4 24 | — | $341.2M | ||
| Q3 24 | — | $377.2M | ||
| Q2 24 | $-25.4M | $232.2M | ||
| Q1 24 | — | $376.5M |
自由现金流BLRXUTHR
| Q4 25 | — | $173.3M | ||
| Q3 25 | — | $351.6M | ||
| Q2 25 | $-2.8M | $129.5M | ||
| Q1 25 | — | $386.3M | ||
| Q4 24 | — | $254.5M | ||
| Q3 24 | — | $300.7M | ||
| Q2 24 | $-25.5M | $187.1M | ||
| Q1 24 | — | $338.3M |
自由现金流率BLRXUTHR
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | -914.1% | 16.2% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 40.2% | ||
| Q2 24 | -472.8% | 26.2% | ||
| Q1 24 | — | 49.9% |
资本支出强度BLRXUTHR
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 26.3% | ||
| Q2 25 | 3.6% | 7.8% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | 1.1% | 6.3% | ||
| Q1 24 | — | 5.6% |
现金转化率BLRXUTHR
| Q4 25 | — | 0.95× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | -52.56× | 0.83× | ||
| Q1 24 | — | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLRX
暂无分部数据
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
